The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.
R. O'Neill, and R. Temple. Clinical pharmacology and therapeutics, 91 (3):
550-4(March 2012)Dades censurades; RCT; Regulació; Imputació múltiple; LOCF.
DOI: 10.1038/clpt.2011.340
Abstract
At the request of the Food and Drug Administration (FDA) and with its funding, the Panel on the Handling of Missing Data in Clinical Trials was created by the National Research Council's Committee on National Statistics. This panel recently published a report(1) with recommendations that will be of use not only to the FDA but also to the entire clinical trial community so that the latter can take measures to improve the conduct and analysis of clinical trials.
%0 Journal Article
%1 ONeill2012
%A O'Neill, R T
%A Temple, R
%D 2012
%J Clinical pharmacology and therapeutics
%K ClinicalTrialsDataMonitoringCommittees ClinicalTrialsasTopic ClinicalTrialsasTopic:standards DataInterpretation DrugApproval Humans InformationStorageandRetrieval Statistical UnitedStates UnitedStatesFoodandDrugAdministration
%N 3
%P 550-4
%R 10.1038/clpt.2011.340
%T The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.
%U http://www.ncbi.nlm.nih.gov/pubmed/22318615
%V 91
%X At the request of the Food and Drug Administration (FDA) and with its funding, the Panel on the Handling of Missing Data in Clinical Trials was created by the National Research Council's Committee on National Statistics. This panel recently published a report(1) with recommendations that will be of use not only to the FDA but also to the entire clinical trial community so that the latter can take measures to improve the conduct and analysis of clinical trials.
@article{ONeill2012,
abstract = {At the request of the Food and Drug Administration (FDA) and with its funding, the Panel on the Handling of Missing Data in Clinical Trials was created by the National Research Council's Committee on National Statistics. This panel recently published a report(1) with recommendations that will be of use not only to the FDA but also to the entire clinical trial community so that the latter can take measures to improve the conduct and analysis of clinical trials.},
added-at = {2023-02-03T11:44:35.000+0100},
author = {O'Neill, R T and Temple, R},
biburl = {https://www.bibsonomy.org/bibtex/27f1ea94c55803392e75083e88a5b0c98/jepcastel},
doi = {10.1038/clpt.2011.340},
interhash = {896ac2dcc4b73aa7f5c66f9ec1040bff},
intrahash = {7f1ea94c55803392e75083e88a5b0c98},
issn = {1532-6535},
journal = {Clinical pharmacology and therapeutics},
keywords = {ClinicalTrialsDataMonitoringCommittees ClinicalTrialsasTopic ClinicalTrialsasTopic:standards DataInterpretation DrugApproval Humans InformationStorageandRetrieval Statistical UnitedStates UnitedStatesFoodandDrugAdministration},
month = {3},
note = {Dades censurades; RCT; Regulació; Imputació múltiple; LOCF},
number = 3,
pages = {550-4},
pmid = {22318615},
timestamp = {2023-02-03T11:44:35.000+0100},
title = {The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.},
url = {http://www.ncbi.nlm.nih.gov/pubmed/22318615},
volume = 91,
year = 2012
}